Abstract
Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosis present in CKD patients also leads to a decline in renal function. Definite data concerning the treatment of heart failure in CKD patients are lacking, because patients with significant renal impairment have mostly been excluded from randomized studies. Nevertheless, it seems that CKD patients should receive similar cardiovascular treatment to that used in patients with normal kidney function, but the doses of drugs ought to be titrated to achieve an optimal effect while avoiding adverse events. Several studies have also shown that despite the high risk, in patients with acute coronary syndrome (ACS), revascularization procedures in patients with CKD appear to be advantageous in the long run and are therefore justified. However, large clinical trials are needed to confirm the benefits and to identify possible disadvantages associated with various methods of treatment.
Keywords: Acute coronary syndrome, chronic kidney disease, coronary interventions, treatment.
Current Vascular Pharmacology
Title:Acute Coronary Syndromes in Patients with Chronic Kidney Disease
Volume: 11 Issue: 5
Author(s): Beata Franczyk-Skóra, Anna Gluba, Maciej Banach, Piotr Rozentryt, Lech Poloński and Jacek Rysz
Affiliation:
Keywords: Acute coronary syndrome, chronic kidney disease, coronary interventions, treatment.
Abstract: Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosis present in CKD patients also leads to a decline in renal function. Definite data concerning the treatment of heart failure in CKD patients are lacking, because patients with significant renal impairment have mostly been excluded from randomized studies. Nevertheless, it seems that CKD patients should receive similar cardiovascular treatment to that used in patients with normal kidney function, but the doses of drugs ought to be titrated to achieve an optimal effect while avoiding adverse events. Several studies have also shown that despite the high risk, in patients with acute coronary syndrome (ACS), revascularization procedures in patients with CKD appear to be advantageous in the long run and are therefore justified. However, large clinical trials are needed to confirm the benefits and to identify possible disadvantages associated with various methods of treatment.
Export Options
About this article
Cite this article as:
Franczyk-Skóra Beata, Gluba Anna, Banach Maciej, Rozentryt Piotr, Poloński Lech and Rysz Jacek, Acute Coronary Syndromes in Patients with Chronic Kidney Disease, Current Vascular Pharmacology 2013; 11 (5) . https://dx.doi.org/10.2174/1570161111311050013
DOI https://dx.doi.org/10.2174/1570161111311050013 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditions
Current Medicinal Chemistry Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Relevance of Excitable Media Theory and Retinal Spreading Depression Experiments in Preclinical Pharmacological Research
Current Neuropharmacology Editorial (Hot Topic: Platelets in Vascular Homeostasis and Inflammation: Current Perspectives from Bench to Bedside)
Current Vascular Pharmacology Prevention of Sudden Cardiac Death in Hemodialysis Patients
Cardiovascular & Hematological Disorders-Drug Targets Ryanodine Receptor - A Novel Therapeutic Target in Heart Disease
Recent Patents on Cardiovascular Drug Discovery <i>In-situ</i> Intestinal Absorption and Pharmacokinetic Investigations of Carvedilol Loaded Supersaturated Self-emulsifying Drug System
Pharmaceutical Nanotechnology Phytoestrogens and Prostate Cancer
Current Drug Targets Development of Genomics-Based Gene Expression Signature Biomarkers in Oncology and Toxicology to Facilitate Drug Discovery and Translational Medicine
Current Bioinformatics Emerging Concepts for Myocardial Late Gadolinium Enhancement MRI
Current Cardiology Reviews Review of the Relationship between Renal and Retinal Microangiopathy in Diabetes Mellitus Patients
Current Diabetes Reviews PREFACE [Hot topic: Nuclear Hormone Receptor Modulators as Targets for Drug Discovery (Guest Editor: Timothy Grese)]
Current Topics in Medicinal Chemistry Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Amidine-Based Bioactive Compounds for the Regulation of Arginine Metabolism
Mini-Reviews in Medicinal Chemistry A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Current Pharmaceutical Design Rheumatoid Arthritis: An Evolutionary Force in Biologics
Current Pharmaceutical Design